Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma. Grimm MO, Schmitz-Drager BJ, Zimmermann U, Grun CB, et al. J Clin Oncol 2022;40:2128-2137.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Grimm MO, Schmitz-Drager BJ, Zimmermann U, Grun CB, et al. Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell Carcinoma. J Clin Oncol 2022;40:2128-2137.
PMID: 35275706